REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
基本信息
- 批准号:9065644
- 负责人:
- 金额:$ 75.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-06-01 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AblationActive SitesAcuteAcyl Coenzyme AAcyltransferaseArachidonic AcidsAttenuatedBioenergeticsBiologicalBiological AssayCalciumCalcium ionCardiacCardiac MyocytesCause of DeathCell membraneCessation of lifeChargeChemicalsChronicCoenzyme A-TransferasesComplexCouplingDiabetes MellitusDiseaseEicosanoidsEmployee StrikesEndocannabinoidsEnergy IntakeEnzymesFatty AcidsFatty acid glycerol estersFunctional disorderGenerationsGeneticHealthHeartHeart DiseasesHeart failureHomeostasisHydrolysisInfarctionInjuryIschemiaKnock-outKnockout MiceLeadLipaseLipidsLysophosphatidylcholinesLysophospholipaseMass Spectrum AnalysisMediatingMediator of activation proteinMembraneMembrane Structure and FunctionMitochondriaMolecularMonoglyceridesMusMutateMyocardialMyocardial ContractionMyocardial IschemiaMyocardiumNecrosisPLA2G6 genePathologicPathway interactionsPhospholipasePhosphorylationPhosphorylation SitePhysiologicalPhysiological ProcessesProductionProtein IsoformsProteinsRegulationReperfusion TherapyRoleSerineSignal TransductionSignaling MoleculeSite-Directed MutagenesisSocietiesStable Isotope LabelingStructureSudden DeathTestingTransacylaseTransgenic OrganismsTriglyceridesVentricular Arrhythmiacalmodulin-dependent protein kinase IIdiabeticdiabetic cardiomyopathydiabetic patientheart cellhemodynamicsinsulin signalinginterdisciplinary approachloss of functionlysophosphatidic acidmetabolomicsmitochondrial dysfunctionmitochondrial permeability transition porenovelnovel therapeuticstransacylation
项目摘要
DESCRIPTION (provided by applicant): Diabetic cardiomyopathy is a complex disorder that emanates from the chronic and excessive use of fatty acids to fuel contractile function in diabetic myocardium due to the lack of insulin signaling. However, the nearly exclusive use of fatty acids for fuel in diabetic myocardium results in widespread metabolomic dysregulation that precipitates multiple deleterious alterations in membrane structure and function. Consequences of these membrane-mediated abnormalities in diabetic myocardium include hemodynamic compromise, defective excitation-contraction coupling and mitochondrial dysfunction that collectively conspire to promote the progression of heart failure in diabetic patients. Moreover, the profound alterations in substrate utilization in diabetic myocardium result in the accumulation
of multiple dysregulated metabolites that lead to maladaptive alterations in interwoven cardiac myocyte signaling networks. Previously, through genetic, pharmacologic and chemical biological approaches, we have identified three major phospholipases and lipases in myocardium iPLA2ß (PNPLA9), iPLA2γ (PNPLA8), and iPLA2ζ (PNPLA2; ATGL) that likely serve as principal mediators of myocardial hemodynamic dysfunction, electrophysiologic alterations and maladaptive remodeling in diabetic myocardium. Recently, we demonstrated that iPLA2γ and its downstream signaling metabolites are key regulators of the mitochondrial permeability transition pore which is responsible for necrosis, necroptosis, and electrical instability in diabetic myocardium subjected to ischemia. Accordingly, in Specific Aim 1, we will use the novel cardiac myocyte specific iPLA2γ conditional knock out mouse we generated to determine if iPLA2γ loss of function attenuates acute ischemic injury, electrophysiologic instability and the maladaptive generation of lipid 2nd messengers in diabetic myocardium. Furthermore, we demonstrated that exposure of mitochondria to calcium ion results in the activation of iPLA2γ leading to the release of arachidonic acid, 2-arachidonoyl lysophosphatidylcholine, and the subsequent production of multiple downstream biologically active lipid 2nd messengers. Accordingly, iPLA2γ-dependent alterations in lipid 2nd messenger production will be examined employing integrative mass spectrometric platforms we developed in conjunction with the cardiac myocyte specific iPLA2γ loss of function mouse. In Specific Aim 2, we will determine the molecular mechanisms through which acyl-CoA facilitates CaMKII phosphorylation and activation of iPLA2ß. The activating phosphosite(s) will be identified, mutated and their mechanistic importance in CaMKII-mediated activation of iPLA2ß in diabetic myocardium and diabetic myocardium rendered ischemic will be explored. In Specific Aim 3, the role(s) of iPLA2ζ (ATGL;PNPLA2) in catalyzing the bidirectional flux of lipids through triglyceride hydrolysis, transacylation and acyltransferase activities will e determined. The participation of iPLA2ζ in generating lipid 2nd messengers in diabetic myocardium will be examined using cardiac myocyte specific iPLA2ζ null mice and the effects of iPLA2ζ genetic ablation on myocardial function in the diabetic state will be explored. Collectively, these studies are a synergistic multidisciplinary approach to identify the chemical mechanisms mediating diabetic cardiomyopathy.
描述(由适用提供):糖尿病心肌病是一种复杂的疾病,它是由于缺乏胰岛素信号传导而源自慢性和过量使用脂肪酸来为糖尿病性心肌促进收缩功能的疾病。然而,在糖尿病心肌中,几乎独有的脂肪酸用于燃料,导致宽度代谢性失调,从而使膜结构和功能上多次删除了变化。这些膜介导的糖尿病心肌异常的后果包括血液动力学妥协,有缺陷的兴奋性诱导偶联和线粒体功能障碍,共同促进糖尿病患者心脏衰竭的进展。此外,糖尿病心肌中底物利用的深刻变化导致积累
以前,通过遗传,药物和化学生物学方法,我们已经确定了IPLA2ß(PNPLA9)心肌(PNPLA9),IPLA2γ(PNPLA8)和IPLA2ζ和IPLA2ζ(PNPLA2; GGL)中的三种主要磷脂酶和脂肪酶(PNPLA8)(PNPLA8)(PNPLA2; ATPLA2; ATPLA2; ATPLA2; ATPLA2;重塑糖尿病心肌。最近,我们证明了IPLA2γ及其下游信号代谢产物是线粒体通透性过渡孔的关键调节孔,该孔导致坏死,坏死和糖尿病心肌的电不稳定性。据此,我们将使用新颖的心肌特异性IPLA2γ条件敲除小鼠,以确定功能的IPLA2γ是否会减少急性缺血性损伤,电生理学不稳定和糖尿病心理中的脂质2nd Messenger的脂质脂质第二次。此外,我们证明,线粒体暴露于钙离子会导致IPLA2γ的激活,从而释放了花生四烯酸,2-芳基二烯酰基溶磷脂酰胆碱,并随后产生多个下游生物学活性的生物学活性Lipid 2nd 2nd Messergers。根据激活的磷材料,将探索,突变,突变,它们在CAMKII介导的IPLA2ß激活中的机理重要性将探索糖尿病心肌和糖尿病心肌呈现的缺血性。在特定的目标3中,将确定IPLA2ζ(ATGL; PNPLA2)在通过甘油三酸酯水解,翻译和酰基转移酶活性催化脂质的双向通量中的作用。 IPLA2ζ参与产生脂质第二使者在糖尿病心肌中的参与将使用心肌细胞特异性IPLA2ζ无小鼠进行检查,以及IPLA2ζ遗传消融对糖尿病状态中心肌功能的影响。总的来说,这些研究是一种协同的多学科方法,用于识别介导糖尿病心肌病的化学机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD W GROSS其他文献
RICHARD W GROSS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD W GROSS', 18)}}的其他基金
Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
- 批准号:
10593961 - 财政年份:2016
- 资助金额:
$ 75.54万 - 项目类别:
Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
- 批准号:
10378709 - 财政年份:2016
- 资助金额:
$ 75.54万 - 项目类别:
NOVEL LIPID 2ND MESSENGERS REGULATING BIOENERGETICS AND SIGNALING IN HUMAN MYOCARDIUM
调节人体心肌生物能量和信号传导的新型脂质第二信使
- 批准号:
9281066 - 财政年份:2016
- 资助金额:
$ 75.54万 - 项目类别:
Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
- 批准号:
10211266 - 财政年份:2016
- 资助金额:
$ 75.54万 - 项目类别:
THE INTEGRATED ROLES OF IPLA2G IN OBESITY, INFLAMMATION AND HEPATIC DYSFUNCTION
IPLA2G 在肥胖、炎症和肝功能障碍中的综合作用
- 批准号:
8817361 - 财政年份:2014
- 资助金额:
$ 75.54万 - 项目类别:
THE INTEGRATED ROLES OF IPLA2G IN OBESITY, INFLAMMATION AND HEPATIC DYSFUNCTION
IPLA2G 在肥胖、炎症和肝功能障碍中的综合作用
- 批准号:
9325506 - 财政年份:2014
- 资助金额:
$ 75.54万 - 项目类别:
Regulation of Myocardial Phospholipases and Lipases in Diabetic Myocardium
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
10551194 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
8483030 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
9309220 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
Regulation of Myocardial Phospholipases and Lipases in Diabetic Myocardium
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
10367196 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
相似海外基金
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
8483030 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
8848116 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
- 批准号:
8666047 - 财政年份:2013
- 资助金额:
$ 75.54万 - 项目类别: